Exothera, LogicBioTherapeutics, and Polyplus Collaborate on Industrial-Scale AAV Manufacturing
Exothera, LogicBioTherapeutics, and Polyplus-transfection, are collaborating on the development of a scalable AAV manufacturing platform.
Viral vector contract development and manufacturing organization (CDMO), Exothera, has announced its collaboration with clinical-stage genetic medicine company, LogicBioTherapeutics, and provider of upstream process solutions, Polyplus-transfection, for the development of a scalable adeno-associated virus (AAV) manufacturing platform.
The project, which was revealed in a June 15, 2022 press release, will be led by Exothera at its facility located in Jumet, Belgium. LogicBio will deliver its proprietary mAAVRx plasmid technology and AAV expertise, and Polyplus will provide access to its FectoVIR-AAV transfection reagent and its process development expertise for large-scale transient processing.
“Exothera’s team is proud to work with the experienced teams at biotech companies like LogicBio and Polyplus,” said Hanna Lesch, chief technology officer at Exothera, in the press release. “The success of AAV-based therapeutics requires a change in the manufacturing paradigm and through this collaboration, we aim to enable a new approach to consistently scale AAV manufacturing.”
“We believe our proprietary mAAVRx™ plasmid technology could dramatically help to improve manufacturing yields and consequently reduce AAV manufacturing costs,” added Matthias Hebben, global vice president, Technology Development at LogicBio, in the press release. “We are hopeful that the work done under this collaboration will be an important step forward in making gene therapy products accessible for a greater number of patients.”
“We are delighted to scale up AAV Viral vector Manufacturing processes to larger bioreactor volumes with innovators in the industry like Exothera and LogicBio,” said Roel Gordijn, chief commercial Officer at Polyplus, in the press release. “The collaboration will use a combination of state-of-the-art manufacturing technologies, innovative plasmid technologies and scalable transfection reagents which will make gene-therapy viral vector therapies affordable.”
Source: Exothera
